A phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) as first-line chemotherapy in advanced gastric cancer: a Chinese single-center experience.
This study aimed at evaluating the efficacy and safety of epirubicin, oxaliplatin, and capecitabine (EOX) in advanced gastric cancer (AGC) patients in the Chinese population. Patients with previously untreated advanced measurable gastric cancer received epirubicin (50 mg/m(2), day 1), oxaliplatin (130 mg/m(2) 2-hour infusion, day 1) and capecitabine (625 mg/m(2) orally, twice daily, days 1-21) every 3 weeks. Of 48 enrolled patients, 47 were evaluable for efficacy and 48 for toxicity. A median of five cycles (range 1-8) was administered. The overall response rate was 51.1% (95% CI 36-66) with two complete responses, 22 partial responses, 16 stable diseases, and 7 progressions. Median progression-free survival was 6.5 months (95% CI 5.6-7.4) and median overall survival was 10.4 months (95% CI 8.8-12.0). Grade 3-4 neutropenia and anemia were observed in 22.9 and 6.3% of patients, respectively. Grade 3-4 nonhematological toxicities included alopecia (18.9%), nausea (8.3%), vomiting (6.3%), diarrhea (6.3%), hand-foot syndrome (4.2%) and neurological toxicity (2.1%). In our experience, the EOX regimen was highly effective, well tolerated and conveniently delivered as first-line chemotherapy for AGC patients in the Chinese population.